GB Patent

GB2410947A — Pharmaceutical compounds

Assigned to Cambridge Laboratories Ltd · Expires 2005-08-17 · 21y expired

What this patent protects

The invention provides novel isomers of dihydrotetrabenazine, namely 3,11b-cis-dihydrotetrabenazine isomers. Also provided are methods for making the isomers, pharmaceutical compositions containing them and their therapeutic uses, in particular the treatment of hyperkinetic movem…

USPTO Abstract

The invention provides novel isomers of dihydrotetrabenazine, namely 3,11b-cis-dihydrotetrabenazine isomers. Also provided are methods for making the isomers, pharmaceutical compositions containing them and their therapeutic uses, in particular the treatment of hyperkinetic movement disorders such as Huntington's disease, hemiballismus, senile chorea, tic, tardive dyskinesia and Tourette's syndrome, and the treatment of depression. The invention further provides synthetic intermediates for use in preparing the isomers of the invention.

Drugs covered by this patent

Patent Metadata

Patent number
GB2410947A
Jurisdiction
GB
Classification
—
Expires
2005-08-17
Drug substance claim
No
Drug product claim
No
Assignee
Cambridge Laboratories Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.